A couple of days ago was extremely busy and tumultuous in the US medical world when it was reported that there was a cure for COVID-19 from the White House meeting. A series of newspaper pages, the information on the bustling Facebook with hundreds of thousands of shares/views. There are 2 things we need to understand:
- The truth is that until now there have been NO COVID-19 DRUGS. - The truth is that up to this point, we are in the stage of having the POTENTIAL to find a cure for COVID-19.
What are these potentials? - One of the potentials proposed is Hydroxychloroquine (also known as Plaquenil or HCQ used to treat malaria, lupus, and arthritis) - It is also possible that HCQ in combination with Z-pak antibiotics (Azithromycin) can help - It is also possible that one of the dozens of other research going on in many laboratories around the world can help
Forecast information: - The combination of HCQ and Z-pak can reduce the amount of virus in the body quickly leading to rapid recovery. Studies on the use of these two drugs so far, though optimistic, are relatively small.
FDA plan: - In the study yesterday, representatives of the FDA (Food and Drug Administration) announced that although HCQ has potential, there will be more research on the effects of HCQ in the treatment of COVID-19. - This means that the FDA will need a large-scale clinical trial and will need to collect factual information from COVID-19 patients who have used the drug worldwide. Does this take a long time? Usually yes. - Until now HCQ has only in vitro data that MAY be effective in treating COVID-19
What does this mean? - The HCQ drug was approved by the FDA in 1955 for three purposes: to treat malaria, lupus, and arthritis. Once the drug has been approved, the physician may allow the patient to use it for OFF-LABEL purposes in the appropriate context. - OFF-LABEL means the effect has NOT been recognized, there is no clear research, and in the research stage ... Patients can voluntarily use it under the guidance and supervision of doctors. - Meanwhile, with the data collected from the OFF-LABEL use cases, scientists will have other studies in parallel to create a drug specifically used for COVID-19. - Therefore, the "Compassionate Use" program has been launched for patients who are in critical condition but have no approved treatments. HCQ is being used for the same purpose in this program for COVID-19 patients.
Scientific Information about HCQ - Not everyone can use HCQ, especially patients with heart, kidney and liver problems. HCQ should be prescribed, used with doctor's supervision. - This drug has side effects to note such as thrombocytopenia, leukocytosis (reduced immunity of the body), cardiovascular disease, convulsions, can cause permanent vision loss if used long term .. Rampant use leads to drug resistance and the world has to deal with more dangerous problems.
Working in the medical field, we have learned these two things: PRECAUTIONS AND CALM. Having the potential does not mean having the end result. - Be careful that every statement from a person working in the health field is always based on clear medical evidence, ensuring the highest possible safety for patients. - Calm down so your statements do not cause confusion in the public opinion - "Not to provide false hope, but to provide hope" is the purpose of the journey to find solutions for COVID-19 according to the representative of FDA, Dr. Stephen Hahn - That is one of the reasons we rarely listed the name of the drug, except for some over-the-counter medicines (without a prescription). This is one of the articles that can be said that the only one we wrote mentioned the drug name.
Until now, there are still many places in the world patients can buy drugs, diagnose and treat themselves. Any haste in the health field, especially during this time, will be more dangerous than good.
In the turmoil of fake news everywhere, if you pay attention, you will see that the mainstream news agencies no one has reported HAS COVID DRUGS 19.
Please take care of your health. Stay healthy and be safe!
Comments